Alnylam Pharmace. buy Stifel Nicolaus
Summary
This prediction ended on 15.09.24 with a price of €240.20. With a performance of 32.41% the BUY prediction by Stifel_Nicolaus was a big success. Stifel_Nicolaus has a follow-up prediction for Alnylam Pharmace. where he still thinks Alnylam Pharmace. is a Buy. Stifel_Nicolaus has 50% into this predictionAlnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.
Performance without dividends (%)
Name | 1w | 1m | 1y |
---|---|---|---|
Alnylam Pharmace. | 6.196% | 6.196% | 42.166% |
iShares Core DAX® | 1.887% | 1.967% | 17.000% |
iShares Nasdaq 100 | 2.316% | -1.227% | 22.986% |
iShares Nikkei 225® | 1.134% | 0.390% | 9.520% |
iShares S&P 500 | 1.821% | 0.790% | 22.957% |
Comments by Stifel_Nicolaus for this prediction
In the thread Alnylam Pharmace. diskutieren
In the thread Trading Alnylam Pharmace.